Loading
A phase 3 trial of Daratumumab, Carfilzomib, Dexamethasone in multiple myeloma, run by AstraZeneca, now recruiting.
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) is a phase 3 interventional study registered as NCT07391657 by AstraZeneca, with 508 participants planned, started 2026-02-23 and due to reach its primary completion in 2028-06-14. Interventions recorded: AZD0120, Daratumumab, Carfilzomib, Dexamethasone, Bortezomib. Conditions listed: Relapsed Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AZD0120, Daratumumab, Bortezomib, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
Shares AZD0120, Relapsed or refractory multiple myeloma, AstraZeneca, Multiple myeloma.
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Daratumumab, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
Shares Pomalidomide, Daratumumab, Bortezomib, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Daratumumab, Dexamethasone.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/